Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome

Abstract

Pathogenesis of erectile dysfunction (ED) is related to endothelial dysfunction and therefore associated with cardiovascular risk factors. Patients with a combination of risk factors, as in metabolic syndrome, are thus likely to have an increased risk of developing endothelial and ED. The angiotensin receptor antagonist irbesartan has been shown to improve endothelial function in cardiovascular high-risk patients, which suggests a beneficial effect of treatment with irbesartan on ED. The aim of the present study was to determine the influence of irbesartan on ED in patients with a metabolic syndrome. A total of 1069 consecutive hypertensive patients with a metabolic syndrome from the Documentation of hypertension and metabolic syndrome in patients with Irbesartan Treatment survey were included. Patients were treated with irbesartan or the combination of irbesartan/hydrochlorothiazide for 6 months. ED was assessed using the international index of erectile function. The Cologne Evaluation Questionnaire of Erectile Dysfunction served as a control. Erectile function increased significantly (P<0.0001) after 6 months of treatment with irbesartan, irrespective of dosage and independent of additional treatment with hydrochlorothiazide. Prevalence of ED declined to 63.7% from 78.5% at baseline, along with a significant increase in orgasmic function (P<0.001) and intercourse satisfaction (P<0.001). Treatment with irbesartan alone, as well as in combination with hydrochlorothiazide is associated with an improvement of sexual desire, frequency of sexual contacts and erectile function in hypertensive patients with the metabolic syndrome. These results suggest a beneficial role of angiotensin receptor antagonists in the treatment of metabolic syndrome, and ED.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. National Institutes of Health. Impotence. NIH Consens State 1992; 10: 1–33.

    Google Scholar 

  2. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U . Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Impot Res 2000; 12: 305–311.

    Article  CAS  PubMed  Google Scholar 

  3. Feldman HA, Johannes CB, Derby CA, Kleinman KP, Mohr BA, Araujo AB et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev Med 2000; 30: 328–338.

    Article  CAS  PubMed  Google Scholar 

  4. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB . Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol 1994; 151: 54–61.

    Article  CAS  PubMed  Google Scholar 

  5. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW . Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141–1148.

    Article  CAS  PubMed  Google Scholar 

  6. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916–1923.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Kifor I, Williams GH, Vickers MA, Sullivan MP, Jodbert P, Dluhy RG . Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum. J Urol 1997; 157: 1920–1925.

    Article  CAS  PubMed  Google Scholar 

  8. Friedrich EB, Teo KK, Bohm M . ACE inhibition in secondary prevention: are the results controversial? Clin Res Cardiol 2006; 95: 61–67.

    Article  CAS  PubMed  Google Scholar 

  9. Llisterri JL, Lozano Vidal JV, Aznar Vicente J, Argaya Roca M, Pol Bravo C, Sanchez Zamorano MA et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci 2001; 321: 336–341.

    Article  CAS  PubMed  Google Scholar 

  10. Dusing R . Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press Suppl 2003; 2: 29–34.

    Article  CAS  PubMed  Google Scholar 

  11. Fogari R, Zoppi A, Poletti L, Marasi G, Mugellini A, Corradi L . Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 2001; 14: 27–31.

    Article  CAS  PubMed  Google Scholar 

  12. Fogari R, Zoppi A, Corradi L, Mugellini A, Poletti L, Lusardi P . Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study. Am J Hypertens 1998; 11: 1244–1247.

    Article  CAS  PubMed  Google Scholar 

  13. Sola S, Mir MQ, Cheema FA, Khan-Merchant N, Menon RG, Parthasarathy S et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation 2005; 111: 343–348.

    Article  CAS  PubMed  Google Scholar 

  14. Ortlepp JR, Breuer J, Eitner F, Kluge K, Kluge R, Floege J et al. Inhibition of the renin-angiotensin system ameliorates genetically determined hyperinsulinemia. Eur J Pharmacol 2002; 436: 145–150.

    Article  CAS  PubMed  Google Scholar 

  15. Lewis EJ, Hunsicker LG, Rodby RA . A clinical trial in type 2 diabetic nephropathy. Am J Kidney Dis 2001; 38: S191–S194.

    Article  CAS  PubMed  Google Scholar 

  16. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A . The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822–830.

    Article  CAS  PubMed  Google Scholar 

  17. Baumhakel M, Werner N, Bohm M, Nickenig G . Circulating endothelial progenitor cells correlate with erectile function in patients with coronary heart disease. Eur Heart J 2006; 27: 2184–2188.

    Article  PubMed  Google Scholar 

  18. Laufs U, Endres M, Custodis F, Gertz K, Nickenig G, Liao JK et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation 2000; 102: 3104–3110.

    Article  CAS  PubMed  Google Scholar 

  19. Pershadsingh HA . Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma. Int J Biochem Cell Biol 2006; 38: 766–781.

    Article  CAS  PubMed  Google Scholar 

  20. Bohm M, Baumhakel M, Probstfield JL, Schmieder R, Yusuf S, Zhao F et al. Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND). Am Heart J 2007; 154: 94–101.

    Article  PubMed  Google Scholar 

  21. Mannino DM, Klevens RM, Flanders WD . Cigarette smoking: an independent risk factor for impotence? Am J Epidemiol 1994; 140: 1003–1008.

    Article  CAS  PubMed  Google Scholar 

  22. Modebe O . Erectile failure among medical clinic patients. Afr J Med Med Sci 1990; 19: 259–264.

    CAS  PubMed  Google Scholar 

  23. Grimm Jr RH, Grandits GA, Prineas RJ, McDonald RH, Lewis CE, Flack JM et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997; 29: 8–14.

    Article  CAS  PubMed  Google Scholar 

  24. Barksdale JD, Gardner SF . The impact of first-line antihypertensive drugs on erectile dysfunction. Pharmacotherapy 1999; 19: 573–581.

    Article  CAS  PubMed  Google Scholar 

  25. Franzen D, Metha A, Seifert N, Braun M, Hopp HW . Effects of beta-blockers on sexual performance in men with coronary heart disease. A prospective, randomized and double blinded study. Int J Impot Res 2001; 13: 348–351.

    Article  CAS  PubMed  Google Scholar 

  26. Silvestri A, Galetta P, Cerquetani E, Marazzi G, Patrizi R, Fini M et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J 2003; 24: 1928–1932.

    Article  CAS  PubMed  Google Scholar 

  27. Wassmann S, Ribaudo N, Faul A, Laufs U, Bohm M, Nickenig G . Effect of atorvastatin 80 mg on endothelial cell function (forearm blood flow) in patients with pretreatment serum low-density lipoprotein cholesterol levels &lt;130 mg/dl. Am J Cardiol 2004; 93: 84–88.

    Article  CAS  PubMed  Google Scholar 

  28. Laufs U, La Fata V, Plutzky J, Liao JK . Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129–1135.

    Article  CAS  PubMed  Google Scholar 

  29. Nangle MR, Cotter MA, Cameron NE . Effects of rosuvastatin on nitric oxide-dependent function in aorta and corpus cavernosum of diabetic mice: relationship to cholesterol biosynthesis pathway inhibition and lipid lowering. Diabetes 2003; 52: 2396–2402.

    Article  CAS  PubMed  Google Scholar 

  30. Bank AJ, Kelly AS, Kaiser DR, Crawford WW, Waxman B, Schow DA et al. The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction. Vasc Med 2006; 11: 251–257.

    Article  PubMed  Google Scholar 

  31. Sowers JR, Neutel JM, Saunders E, Bakris GL, Cushman WC, Ferdinand KC et al. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich) 2006; 8: 470–480.

    Article  CAS  Google Scholar 

  32. Carson C, Shabsigh R, Segal S, Murphy A, Fredlund P, Kuepfer C . Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers. Urology 2005; 65: 353–359.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The DO-IT-EDE study was sponsored by a grant of Bristol-Myers-Squibb, Munich, Germany, and was conducted with the help of GKM Gesellschaft für Therapieforschung, Munich, Germany. The authors thank Dr F Münzel, BMS, Germany, who helped developing the study and H Gnann, GKM Gesellschaft für Therapieforschung, Germany, for statistical analysis.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to M Baumhäkel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baumhäkel, M., Schlimmer, N., Böhm, M. et al. Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome. Int J Impot Res 20, 493–500 (2008). https://doi.org/10.1038/ijir.2008.28

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijir.2008.28

Keywords

This article is cited by

Search

Quick links